AU2006321794A1 - Compositions and methods for inducing the activation of immature monocytic dendritic cells - Google Patents
Compositions and methods for inducing the activation of immature monocytic dendritic cells Download PDFInfo
- Publication number
- AU2006321794A1 AU2006321794A1 AU2006321794A AU2006321794A AU2006321794A1 AU 2006321794 A1 AU2006321794 A1 AU 2006321794A1 AU 2006321794 A AU2006321794 A AU 2006321794A AU 2006321794 A AU2006321794 A AU 2006321794A AU 2006321794 A1 AU2006321794 A1 AU 2006321794A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- antigen
- tumor
- cell
- dendritic cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000004443 dendritic cell Anatomy 0.000 title claims description 380
- 238000000034 method Methods 0.000 title claims description 83
- 230000001939 inductive effect Effects 0.000 title claims description 36
- 230000004913 activation Effects 0.000 title description 20
- 239000000203 mixture Substances 0.000 title description 9
- 239000000427 antigen Substances 0.000 claims description 206
- 108091007433 antigens Proteins 0.000 claims description 206
- 102000036639 antigens Human genes 0.000 claims description 206
- 210000004027 cell Anatomy 0.000 claims description 156
- 239000002243 precursor Substances 0.000 claims description 90
- 239000000758 substrate Substances 0.000 claims description 76
- 210000001519 tissue Anatomy 0.000 claims description 74
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 70
- 230000035800 maturation Effects 0.000 claims description 67
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- 206010028980 Neoplasm Diseases 0.000 claims description 50
- 102000004388 Interleukin-4 Human genes 0.000 claims description 32
- 108090000978 Interleukin-4 Proteins 0.000 claims description 32
- 210000004881 tumor cell Anatomy 0.000 claims description 31
- 229940028885 interleukin-4 Drugs 0.000 claims description 29
- 230000024245 cell differentiation Effects 0.000 claims description 28
- 230000001580 bacterial effect Effects 0.000 claims description 24
- 239000013592 cell lysate Substances 0.000 claims description 22
- 238000000338 in vitro Methods 0.000 claims description 21
- 238000002360 preparation method Methods 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 20
- 102000003816 Interleukin-13 Human genes 0.000 claims description 17
- 108090000176 Interleukin-13 Proteins 0.000 claims description 17
- 230000004069 differentiation Effects 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 102000003812 Interleukin-15 Human genes 0.000 claims description 13
- 108090000172 Interleukin-15 Proteins 0.000 claims description 13
- 208000005017 glioblastoma Diseases 0.000 claims description 13
- 102000008070 Interferon-gamma Human genes 0.000 claims description 11
- 108010074328 Interferon-gamma Proteins 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 11
- 229960003130 interferon gamma Drugs 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 8
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 210000002307 prostate Anatomy 0.000 claims description 6
- 210000000481 breast Anatomy 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000037841 lung tumor Diseases 0.000 claims description 4
- 206010073131 oligoastrocytoma Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 208000023958 prostate neoplasm Diseases 0.000 claims 3
- 230000004044 response Effects 0.000 description 27
- 230000028993 immune response Effects 0.000 description 26
- 210000001616 monocyte Anatomy 0.000 description 25
- 102000004127 Cytokines Human genes 0.000 description 21
- 108090000695 Cytokines Proteins 0.000 description 21
- 238000001994 activation Methods 0.000 description 20
- 102100035793 CD83 antigen Human genes 0.000 description 17
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 17
- 239000006166 lysate Substances 0.000 description 16
- 230000008569 process Effects 0.000 description 13
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 12
- 210000000265 leukocyte Anatomy 0.000 description 12
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 12
- 230000005867 T cell response Effects 0.000 description 11
- 239000004033 plastic Substances 0.000 description 10
- 229920003023 plastic Polymers 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000003308 immunostimulating effect Effects 0.000 description 9
- 102000006354 HLA-DR Antigens Human genes 0.000 description 8
- 108010058597 HLA-DR Antigens Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000004041 dendritic cell maturation Effects 0.000 description 8
- -1 imidazoquinoline compound Chemical class 0.000 description 8
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 7
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 7
- 210000000612 antigen-presenting cell Anatomy 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 239000003104 tissue culture media Substances 0.000 description 7
- 230000006044 T cell activation Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 238000009295 crossflow filtration Methods 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000001960 triggered effect Effects 0.000 description 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 3
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
- 108091054438 MHC class II family Proteins 0.000 description 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 3
- 102000002689 Toll-like receptor Human genes 0.000 description 3
- 108020000411 Toll-like receptor Proteins 0.000 description 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 208000022362 bacterial infectious disease Diseases 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000001821 langerhans cell Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012465 retentate Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100035703 Prostatic acid phosphatase Human genes 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 description 2
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011124 ex vivo culture Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 229940100994 interleukin-7 Drugs 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
- RXNTZIJLOZMJTM-UHFFFAOYSA-N 2-(2h-quinolin-1-yl)ethanol Chemical compound C1=CC=C2N(CCO)CC=CC2=C1 RXNTZIJLOZMJTM-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 101100069857 Caenorhabditis elegans hil-4 gene Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 1
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 1
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 description 1
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 1
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 210000004544 dc2 Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 230000007193 modulation by symbiont of host erythrocyte aggregation Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical compound FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000005135 veiled cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2313—Interleukin-13 (IL-13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/24—Interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2013206016A AU2013206016B2 (en) | 2005-12-08 | 2013-05-24 | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74888505P | 2005-12-08 | 2005-12-08 | |
| US60/748,885 | 2005-12-08 | ||
| PCT/US2006/047083 WO2007067782A2 (en) | 2005-12-08 | 2006-12-08 | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013206016A Division AU2013206016B2 (en) | 2005-12-08 | 2013-05-24 | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2006321794A1 true AU2006321794A1 (en) | 2007-06-14 |
Family
ID=38123555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2006321794A Abandoned AU2006321794A1 (en) | 2005-12-08 | 2006-12-08 | Compositions and methods for inducing the activation of immature monocytic dendritic cells |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20080254537A1 (https=) |
| EP (3) | EP1957634A4 (https=) |
| JP (7) | JP5954918B2 (https=) |
| KR (6) | KR20080109717A (https=) |
| CN (2) | CN101336291A (https=) |
| AR (1) | AR056851A1 (https=) |
| AU (1) | AU2006321794A1 (https=) |
| BR (1) | BRPI0619499A2 (https=) |
| CA (1) | CA2632263C (https=) |
| CR (1) | CR10048A (https=) |
| IL (2) | IL191930A (https=) |
| RU (1) | RU2008122550A (https=) |
| TW (1) | TW200800252A (https=) |
| WO (1) | WO2007067782A2 (https=) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2950109C (en) | 2000-10-27 | 2019-02-19 | John W. Hadden | Vaccine immunotherapy for immune suppressed patients |
| US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
| ES2430389T3 (es) * | 2008-04-14 | 2013-11-20 | Irx Therapeutics, Inc. | Procedimiento modificado de fabricación de IRX-2 |
| US8728806B2 (en) | 2008-12-06 | 2014-05-20 | The Board Of Regents, The University Of Texas System | Methods and compositions related to Th-1 dendritic cells |
| WO2010115229A1 (en) * | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| MX2011012147A (es) | 2009-05-15 | 2012-06-19 | Irx Therapeutics Inc | Inmunoterapia de vacuna. |
| KR101911380B1 (ko) * | 2009-07-24 | 2018-10-25 | 로드아일랜드하스피틀 | 아스파라기닐-β-히드록실라제 발현 종양을 위한 수지상 세포 백신 |
| US20120183518A1 (en) * | 2009-08-24 | 2012-07-19 | Hong Jiang | Assay for determining health of cd8+ t cells |
| AU2010307075B2 (en) | 2009-10-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Granulysin in immunotherapy |
| CN103097543A (zh) | 2009-12-08 | 2013-05-08 | 伊尔克斯治疗有限公司 | 逆转朗格汉斯细胞免疫抑制的方法 |
| US9476029B2 (en) * | 2010-11-13 | 2016-10-25 | Lung-Ji Chang | Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells |
| NL2009102C2 (en) * | 2012-07-02 | 2014-01-06 | Dcprime B V | Method for dc-loading. |
| TWI503414B (zh) * | 2012-07-05 | 2015-10-11 | Fullhope Biomedical Co Ltd | 一種製備專一性ｔ細胞之配方、方法及其配方製備方法 |
| US9744193B2 (en) | 2012-09-06 | 2017-08-29 | Orbis Health Solutions Llc | Tumor lysate loaded particles |
| AU2020203845C1 (en) * | 2012-09-06 | 2022-08-11 | Orbis Health Solutions, Llc | Tumor lysate loaded particles |
| AU2013359392C1 (en) | 2012-12-12 | 2016-12-08 | Orbis Health Solutions, Llc | Compositions and methods for tissue regeneration |
| EP2913394B1 (en) * | 2012-12-18 | 2016-06-22 | Immunicum AB | Co-differentiation and activation of monocytes from allogeneic donors to provide pro-inflammatory dendritic cells |
| CN112891522A (zh) * | 2013-09-05 | 2021-06-04 | 奥比思健康解决方案有限责任公司 | 装载了肿瘤裂解物的微粒 |
| CN103756960A (zh) * | 2013-12-04 | 2014-04-30 | 深圳市合一康生物科技有限公司 | 一种高毒性、高增值能力的人d-cik细胞的专用试剂盒 |
| CN103784950A (zh) * | 2014-01-22 | 2014-05-14 | 北京弘润源生物技术有限公司 | 乳腺癌特异抗原表位多肽负载的树突状细胞疫苗制备及其试剂盒 |
| WO2015134606A1 (en) | 2014-03-05 | 2015-09-11 | Orbis Health Solutions Llc | Vaccine delivery systems using yeast cell wall particles |
| CN103800897B (zh) * | 2014-03-12 | 2017-03-22 | 李金珍 | 一种肿瘤特异抗原表位多肽负载的树突状细胞疫苗制备方法及其试剂盒 |
| ES2817325T3 (es) * | 2014-06-23 | 2021-04-07 | Jw Creagene Inc | Procedimiento de preparación de células dendríticas con aumento de expresión génica específica, y composición para tratar o prevenir enfermedades autoinmunes, conteniendo células dendríticas preparadas utilizando el mismo |
| WO2016145578A1 (en) | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| JP6980650B2 (ja) * | 2015-09-15 | 2021-12-15 | ノースウエスト バイオセラピューティクス，インコーポレイティド | 進行したがんを有する被験体のための活性化樹状細胞組成物および免疫療法処置に関する方法 |
| CN105670994A (zh) * | 2016-02-28 | 2016-06-15 | 深圳爱生再生医学科技有限公司 | Dc诱导剂及其应用 |
| CN105647867A (zh) * | 2016-02-28 | 2016-06-08 | 深圳爱生再生医学科技有限公司 | 诱导树突状细胞成熟的方法和树突状细胞 |
| JP7185530B2 (ja) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス， インコーポレイテッド | 免疫細胞機能を促進するための方法および組成物 |
| CN109844100A (zh) * | 2016-09-01 | 2019-06-04 | 株式会社理研免疫再生医学 | 制备天然杀伤t(nkt)细胞刺激性树突细胞的方法及制备含有nkt细胞刺激性树突细胞和nkt细胞的细胞组合物的方法 |
| EP3518942A4 (en) * | 2016-09-29 | 2020-05-27 | Hadasit Medical Research Services&Development Ltd. | DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE |
| JP7285828B2 (ja) | 2017-09-05 | 2023-06-02 | トルク セラピューティクス， インコーポレイテッド | 治療用タンパク質組成物ならびにその作製および使用方法 |
| CN109957548B (zh) * | 2017-12-26 | 2022-03-18 | 上海尚泰生物技术有限公司 | 一种基因修饰的树突状细胞疫苗 |
| JP6881332B2 (ja) * | 2018-01-29 | 2021-06-02 | 株式会社三洋物産 | 遊技機 |
| JP6881333B2 (ja) * | 2018-01-29 | 2021-06-02 | 株式会社三洋物産 | 遊技機 |
| JP6881331B2 (ja) * | 2018-01-29 | 2021-06-02 | 株式会社三洋物産 | 遊技機 |
| WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
| JP2021533759A (ja) * | 2018-08-10 | 2021-12-09 | ユーティレックス カンパニー リミテッド | 癌抗原特異的ｃｄ８＋ｔ細胞を調製および凍結保存するための方法 |
| CN110106145B (zh) * | 2019-06-12 | 2021-02-12 | 蓝莲(杭州)生物科技有限公司 | 一种未成熟树突状细胞培养液及其未成熟树突状细胞的制备方法 |
| WO2021230704A1 (ko) * | 2020-05-15 | 2021-11-18 | 서울대학교 산학협력단 | 지방조직에서 분리된 기질혈관분획의 수지상세포의 활성화 기능을 이용한 면역 반응 증진용 조성물 |
| KR102753583B1 (ko) * | 2021-11-11 | 2025-01-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물 |
| KR102818249B1 (ko) * | 2021-11-11 | 2025-06-10 | 의료법인 명지의료재단 | Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT633929E (pt) | 1992-04-01 | 2004-07-30 | Merix Bioscience Inc | Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios |
| US5788963A (en) | 1995-07-31 | 1998-08-04 | Pacific Northwest Cancer Foundation | Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy |
| US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
| CA2286819A1 (en) * | 1997-04-17 | 1998-10-22 | Flossie Wong-Staal | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US6558951B1 (en) | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
| AU2002326463A1 (en) | 2001-07-25 | 2003-02-17 | Northwest Biotherapeutics, Inc. | Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors |
| CN1636229B (zh) * | 2001-09-06 | 2012-12-19 | 西北生物治疗药物公司 | 引发单核树突细胞和t细胞th-1应答的组合物和方法 |
| WO2004000444A1 (en) | 2002-06-19 | 2003-12-31 | Northwest Biotherapeutics, Inc. | Tangential flow filtration devices and methods for leukocyte enrichment |
| AT412145B (de) * | 2002-09-13 | 2004-10-25 | Forsch Krebskranke Kinder | Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen |
| ES2321939T3 (es) * | 2003-02-27 | 2009-06-15 | Northwest Biotherapeutics, Inc. | Generacion de celulas dendriticas a partir de celulas precursoras dendriticas monociticas con gm-csf en ausencia de citoquinas adicionales. |
-
2006
- 2006-12-08 KR KR1020087016423A patent/KR20080109717A/ko not_active Ceased
- 2006-12-08 AU AU2006321794A patent/AU2006321794A1/en not_active Abandoned
- 2006-12-08 CA CA2632263A patent/CA2632263C/en active Active
- 2006-12-08 TW TW095145931A patent/TW200800252A/zh unknown
- 2006-12-08 EP EP06848532A patent/EP1957634A4/en not_active Ceased
- 2006-12-08 JP JP2008544561A patent/JP5954918B2/ja active Active
- 2006-12-08 CN CNA2006800520283A patent/CN101336291A/zh active Pending
- 2006-12-08 WO PCT/US2006/047083 patent/WO2007067782A2/en not_active Ceased
- 2006-12-08 EP EP20196461.6A patent/EP3805367A1/en active Pending
- 2006-12-08 KR KR1020187011878A patent/KR20180049169A/ko not_active Ceased
- 2006-12-08 BR BRPI0619499-0A patent/BRPI0619499A2/pt not_active Application Discontinuation
- 2006-12-08 EP EP16170001.8A patent/EP3072958A1/en not_active Withdrawn
- 2006-12-08 KR KR1020227026051A patent/KR20220113543A/ko not_active Ceased
- 2006-12-08 KR KR1020237044465A patent/KR20240005984A/ko not_active Ceased
- 2006-12-08 US US12/096,419 patent/US20080254537A1/en not_active Abandoned
- 2006-12-08 CN CN201310523196.8A patent/CN103589684A/zh active Pending
- 2006-12-08 RU RU2008122550/13A patent/RU2008122550A/ru not_active Application Discontinuation
- 2006-12-08 KR KR1020157017377A patent/KR20150082688A/ko not_active Ceased
- 2006-12-08 KR KR1020217002605A patent/KR20210013327A/ko not_active Ceased
- 2006-12-11 AR ARP060105446A patent/AR056851A1/es unknown
-
2008
- 2008-06-03 IL IL191930A patent/IL191930A/en active IP Right Grant
- 2008-06-05 CR CR10048A patent/CR10048A/es not_active Application Discontinuation
-
2012
- 2012-06-08 US US13/492,693 patent/US20120244620A1/en active Pending
-
2013
- 2013-08-05 JP JP2013162033A patent/JP2013223517A/ja active Pending
- 2013-11-10 IL IL229348A patent/IL229348B/en active IP Right Grant
-
2016
- 2016-02-26 JP JP2016035257A patent/JP2016105725A/ja not_active Withdrawn
-
2017
- 2017-06-22 JP JP2017122256A patent/JP2017158595A/ja not_active Withdrawn
-
2018
- 2018-12-21 JP JP2018238996A patent/JP2019062904A/ja not_active Withdrawn
-
2021
- 2021-01-04 JP JP2021000066A patent/JP2021045176A/ja not_active Withdrawn
-
2023
- 2023-10-10 JP JP2023175234A patent/JP2023171524A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2632263C (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
| JP2009518045A5 (https=) | ||
| AU2010201319B2 (en) | Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines | |
| EP2322603B1 (en) | Compositions and methods for priming monocytic dendritic cells and T cells for Th1 response | |
| CA2509058A1 (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors | |
| AU2013206016B2 (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
| HK40051623A (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
| HK1193842A (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
| MX2008007289A (es) | Composiciones y metodos para inducir la activacion de celulas dendriticas monociticas inmaduras | |
| HK1128161A (en) | Compositions and methods for inducing the activation of immature monocytic dendritic cells | |
| AU2016228284B2 (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors | |
| AU2013234394B2 (en) | Administration of dendritic cells partially matured in vitro for the treatment of tumors | |
| HK1157819B (en) | Compositions and methods for priming monocytic dendritic cells and t cells for th1 response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |